TERN

NextRoll Launches Latest Third-Party Cookieless Testing in Google’s Privacy Sandbox

Retrieved on: 
星期二, 四月 2, 2024
Sandbox, TERN, CMA, SAN, Privacy Sandbox, United, Privacy, Ecosystem, API, ID, OpenX, ARA, Advertising

SAN FRANCISCO, April 02, 2024 (GLOBE NEWSWIRE) -- NextRoll , the San Francisco-based marketing technology company delivering products for ambitious marketers to grow their businesses, today announced the launch of its latest Privacy Sandbox test.

Key Points: 
  • SAN FRANCISCO, April 02, 2024 (GLOBE NEWSWIRE) -- NextRoll , the San Francisco-based marketing technology company delivering products for ambitious marketers to grow their businesses, today announced the launch of its latest Privacy Sandbox test.
  • In addition, NextRoll is also testing the efficacy of alternative probabilistic and deterministic ID solutions and how they compare to Privacy Sandbox results.
  • “This initial testing phase is just the beginning of our collaborative efforts with NextRoll.
  • Through this testing, NextRoll aims to empower marketers with powerful tools for targeted advertising while prioritizing user privacy.

Terns Achieves Primary Endpoint and All Secondary Endpoints in Phase 2a DUET Trial of THR-β Agonist TERN-501 in NASH

Retrieved on: 
星期二, 八月 8, 2023
FXR, Houston Methodist Hospital, Therapy, NASH, Week, Steatohepatitis, Triglyceride, Liver disease, CT1, SHBG, TERN, Bangladesh Technical Education Board, Medicine, Plasma, Fibrosis, Patient, DUET, LDL, Liver, Apolipoprotein B, FDA, GI, Safety, Medical imaging, Pharmaceutical industry

FOSTER CITY, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, non-alcoholic steatohepatitis (NASH) and obesity, today reported positive top-line results from the Phase 2a DUET clinical trial of TERN-501, an orally-administered thyroid hormone receptor-beta (THR-β) agonist, administered as a monotherapy or in combination with TERN-101, a liver-distributed farnesoid X receptor (FXR) agonist, for the treatment of NASH.

Key Points: 
  • TERN-501 monotherapy demonstrated improvement or trends toward improvement in plasma lipid parameters, such as LDL-C, HDL-C, triglycerides, and apolipoprotein B (ApoB).
  • TERN-501 was generally well tolerated, with adverse events (AEs) being generally mild and evenly distributed across all arms, including placebo.
  • TERN-101 safety and tolerability findings were generally consistent with the Phase 2a LIFT trial.
  • A replay of the call will also be available on the Events page of the Investor Relations section of the Terns website for 30 days.